Prevalence of metabolic syndrome among human immunodeficiency virus-infected subjects is widely influenced by the diagnostic criteria

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 5, 2011, Pages 345-351

  Cubero, J M ^a   Domingo, P ^a   Sambeat, M ^a   Ordonez Llanos J ^a   Rodriguez Espinosa, J ^a   Sanchez Quesada J L ^a   Perez A ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; HEALTH EDUCATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 80053524150     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2010.0129     Document Type: Article

References (67)

1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; for the Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26. (Pubitemid 32619279)
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58. (Pubitemid 28190689)
3. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997;25:937-938. (Pubitemid 27443878)
4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351:867-870. (Pubitemid 28121175)
5. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor- associated hyperglycaemia. Lancet 1997;350:713-714. (Pubitemid 127739261)
6. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus infection. Bethesda, MD: FDA Public Health Advisory, June 11, 1997.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099. (Pubitemid 29278477)
8. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983-1998: The Frankfurt HIV-cohort study. Eur J Med Res 2000;5:329-333.
9. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002;25:1253-1254.
10. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-734.
11. Jericó C, Knobel H, Montero M, Ordonez-Llanos J, Guelar A, Gimeno JL, Saballs P, Lopez-Colomes JL, Pedro-Botet J. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005; 28:132-137. (Pubitemid 40095795)
12. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003;21:1377-1382.
13. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care 2007;30: 113-119. (Pubitemid 46052508)
14. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S on behalf of the INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-2453. (Pubitemid 350145176)
15. Bonfanti P, De Socio GL, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Madeddu G, Orofino G, Valsecchi L, Vitiello P, Menzaghi B, Magni C, Ricci E. Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res 2010;8:165-171.
16. Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, Zinman B, Haffner SM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003;52:2740-2747. (Pubitemid 37339703)
17. Goodman E, Daniels SR, Morrison JA, Huang B, Dolan LM. Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. J Pediatr 2004;145: 445-451. (Pubitemid 39345978)
18. Ko GT, Cockram CS, Chow CC, Yeung V, Chan W-B, So WY, Chan NN, Chan J C-N. High prevalence of metabolic syndrome in Hong Kong Chinese-comparison of three diagnostic criteria. Diabetes Res Clin Pract 2005;69:160-168. (Pubitemid 40943481)
19. Martínez Candela J, Franch Nadal J, Romero Ortiz J, Canovas Dominguez C, Gallardo Martin A, Lopez Yepes ML. Predictive capacity of the diagnostic criteria of metabolic syndrome on the insulin-resistance and the coronary risk. Med Clin (Barc) 2007;129:601-606.
20. Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive Summary of the Third National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
21. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443.
22. The IDF consensus Worldwide definition of the metabolic syndrome. International Diabetes Federation, 2005.
23. Domingo P, Sambeat MA, Perez A, Ordonez J, Rodriguez J, Vazquez G. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: Role of physical activity as a protective factor. Antivir Ther 2003;8:223-231. (Pubitemid 36960896)
24. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32:292-300. (Pubitemid 24033886)
25. American College of Endocrinology Task Force on the Insulin Resistance Syndrome: American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. Endocr Pract 2003;9:236-252.
26. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M-R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689. (Pubitemid 32893993)
27. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 2002;288:2709-2716. (Pubitemid 35403784)
28. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM; San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: The San Antonio heart study. Diabetes Care 2003; 26:3153-3159. (Pubitemid 37339513)
29. Lorenzo C., Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13. (Pubitemid 46052493)
30. Cameron AJ, Zimmet PZ, Soderberg S, Alberti KGMM, Sicree R, Tuomilehto J, Chitson P, Shaw JE. The metabolic syndrome as a predictor of incident diabetes mellitus in Mauritius. Diabet Med 2007;24:1460-1469. (Pubitemid 350179441)
31. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin N Am 2004; 33:417-429. (Pubitemid 38684163)
32. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600 (Pubitemid 38766337)
33. Grundy SM. What is the contribution of obesity to the metabolic syndrome? Endocrinol Metab Clin N Am 2004;33: 267-282. (Pubitemid 38680630)
34. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001;24:1758-1763. (Pubitemid 33716478)
35. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin N Am 2007;91: 1063-1077, viii. (Pubitemid 47625441)
36. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-581. (Pubitemid 36929310)
37. Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G, Savorani G, Zocchi D, Melchionda N. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with type 2 diabetes. Diabet Med 2004;21:383-387. (Pubitemid 38519677)
38. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-1257. (Pubitemid 39202341)
39. Balkau B, Charles MA, Drivsholm T, Borch-Johnson K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B; European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-376. (Pubitemid 35434310)
40. Fourie CM, Van Rooyen JM, Kruger A, Schutte AE. Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population. Lipids 2010;45:73-80.
41. Badiou S, Thiebaut R, Aurillac-Lavignolle V, Dabis F, Laporte F, Cristol JP, Mercie P; Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). Association of non- HDL cholesterol with subclinical atherosclerosis in HIVpositive patients. J Infect 2008;57:47-54.
42. Martínez Candela J, Franch Nadal J, Romero Ortiz J, Canovas Dominguez C, Gallardo Martin A, Paez Perez M. Prevalence of metabolic syndrome in the adult population of Yecla (Murcia). Degree of agreement between three definitions of it. Aten Primaria 2006;38:72-79. (Pubitemid 44204750)
43. Alegría E, Cordero A, Laclaustra M, Grima A, Leon M, Casanovas J, Luengo E, del Rio A, Ferreira I. [Prevalence of metabolic syndrome in the Spanish working population: MESYAS registry.] Rev Esp Cardiol 2005;58:797-806. (Pubitemid 41131489)
44. Viñ es JJ, Díez J, Guembe MJ, Gonzalez P, Amezqueta C, Barba J, Sobejano I, Martinez Vila E, Grijalba AM, Serrano M, Moreno C, Los-Arcos E, Guerrero D. [Study of vascular risk in Navarre: objectives and design. Prevalence of metabolic syndrome and of vascular risk factors.] An Sist Sanit Navar 2007;30:113-124. (Pubitemid 46740425)
45. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, Gonzalez- Sanchez JL, Seclen S, Villena A. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program-Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006;29:685-691. (Pubitemid 44115374)
46. Calbo Mayo JM, Terrancle de Juan I, Fernández Jiménez P, Rodriguez Martin MJ, Marinez Diaz V, Santisteban Lopez Y, Navarro Martinez A, Saez Mendez L, Gomez Garrido J, Moreno Salcedo J, Vera Hernanadez J, Fuster Lluch O, Beato JL, Bieda JM, Solera Santos J; Grupo de Estudio Sindrome Metabolico de Albacete. [Prevalence of metabolic syndrome in the province of Albacete (Spain).] Rev Clin Esp 2007; 207:64-68. (Pubitemid 46474379)
47. Marcos Sánchez F, Albo Castañ o MI, Arbol Linde F, Viana Alonso A, Franco Moreno AI, Casallo Blanco S. [Prevalence of the metabolic syndrome in the patients infected with human immunodeficiency virus] An Med Interna 2004;21:461-462. (Pubitemid 39452766)
48. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S; on behalf of the INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007;21:2445-2453. (Pubitemid 350145176)
49. Bernal E, Masiá M., Padilla S, Martin-Hidalgo A, Gutierrez F. [Prevalence and characteristics of metabolic syndrome among HIV-infected patients from a Mediterranean cohort.] Med Clin (Barc) 2007;128:172-175. (Pubitemid 46382324)
50. Howard BV, Criqui MH, Curb JD, Rodabough R, Safford MM, Santoro N, Wilson AC, Wylie-Rosett J. Risk factor clustering in the insulin resistance syndrome and its relationship to cardiovascular disease in postmenopausal white, black, hispanic, and Asian/Pacific Islander women. Metabolism 2003;52:362-371. (Pubitemid 36401683)
51. Corella D, Ordovas JM. The metabolic syndrome: A crossroad for genotype-phenotype associations in atherosclerosis. Curr Atheroscler Rep 2004;6:186-196. (Pubitemid 38898917)
52. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23: 35-43. (Pubitemid 30123263)
53. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz J-M, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 2002;16:F1-F8. (Pubitemid 34274457)
54. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2002;87:4611-4615. (Pubitemid 35247049)
55. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005;118(Suppl 2):23S-28S.
56. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkina AJ, Klein RL, Garvey WT. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27:978-983. (Pubitemid 38420225)
57. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004;53:1195-1200. (Pubitemid 38569003)
58. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352: 48-62. (Pubitemid 40075680)
59. Friis-Moller N, Sabin CA, Weber R, D'arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
60. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-1608. (Pubitemid 38451715)
61. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512. (Pubitemid 47037350)
62. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486. (Pubitemid 38393320)
63. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-1132.
64. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyorala K; DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: A meta-analysis of data from eleven prospective studies. Diabetologia 2004;47:1245-1256. (Pubitemid 39093320)
65. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003;63:2555-2574 (Pubitemid 37491560)
66. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: Reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 2002;112:275-280. (Pubitemid 34219440)
67. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007;30:1219-1225. (Pubitemid 46684651)